Just 8-10 GCC neurologists manage 70-80% of confirmed myasthenia gravis, yet 30-40% are first misdiagnosed as thyroid myopathy.

Myasthenia gravis affects an estimated 6,000 to 10,000 patients across the GCC, or 14 to 20 per 100,000, diagnosed via acetylcholine receptor antibody testing available at specialist neurology and immunology laboratories including KFSH&RC, AUH, Hamad Medical Corporation, and SKMC. The region's high background prevalence of thyroid disease creates a significant diagnostic confounder: thyroid eye disease and thyroid myopathy produce similar ptosis and fatigable weakness, and an estimated 30% to 40% of GCC MG patients are misdiagnosed as thyroid myopathy at first presentation, a distinctly GCC-shaped diagnostic trap rarely emphasised in Western literature.

That diagnostic delay has clinical consequences: GCC case series show 60% to 70% of patients present at MGFA Class III to IV, moderate-severe oculobulbar and limb weakness, versus approximately 40% in European series, with myasthenic crisis occurring at a higher proportion, tied to delayed diagnosis and late immunosuppressive therapy. Thymoma, present in 10% to 15% of MG patients, is worked up in most tertiary GCC referrals but not routinely elsewhere, and thymectomy capacity for non-thymoma cases remains limited. The concentration is stark: an estimated 8 to 10 neurologists across KSA, UAE, and Qatar tertiary centres manage 70% to 80% of all confirmed GCC generalised MG.

A thyroid look-alike hides myasthenia gravis until disease is already advanced.

Five questions this report answers:

Q1 - How does the thyroid-disease diagnostic confounder shape GCC MG time-to-diagnosis?

Q2 - Which 8-10 GCC neurologists manage most confirmed generalised MG, and what does concentration mean commercially?

Q3 - What is the NPHC/MOH formulary trajectory for efgartigimod against the pyridostigmine-plus-steroid backbone?

Q4 - What diagnostic and access barriers define the addressable GCC myasthenia gravis market?

Q5 - How often does thymoma occur in MG patients, and where is it worked up in the GCC?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#MyastheniaGravis #Neurology #FcRn #GCCHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/myasthenia-gravis/gcc/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/